Boehringer adds recheck option to equine PPID testing program: full analysis

Boehringer Ingelheim is expanding its IDPPID testing program with a new recheck option aimed at horses newly diagnosed with pituitary pars intermedia dysfunction and started on Prascend. Beginning in the spring 2026 testing period, eligible cases can be reevaluated through the program, giving equine veterinarians another touchpoint to assess endocrine response and clinical progression after treatment begins. The company announced the update May 11, 2026, as the spring testing window opened. (equimanagement.com)

The move builds on a long-running industry program that Boehringer says has tested more than 65,000 horses since 2013. PPID remains one of the most common endocrine disorders in older horses, with Boehringer citing an estimated prevalence of 21% in horses older than 15 years. Over time, the company has positioned IDPPID.com not just as a testing portal, but as a broader education hub for diagnosis, interpretation, forage testing, and ongoing management resources for veterinarians and pet parents. (equimanagement.com)

Under the new structure, veterinarians can recheck eligible horses using ACTH, insulin, and glucose testing, while also tracking changes in the clinical signs seen at diagnosis. Boehringer technical manager Steve Grubbs, DVM, PhD, DACVIM, said the recheck is intended to provide “additional valuable information” to help guide treatment protocols and improve understanding of PPID progression. The company highlighted familiar early signs such as attitude changes, reduced performance, delayed shedding, and topline loss, as well as later-stage findings including recurrent infections, exercise intolerance, and generalized muscle atrophy. (equimanagement.com)

The broader clinical context supports that emphasis on follow-up. Consensus-style recommendations hosted on IDPPID.com advise evaluating clinical signs, with or without endocrine testing, one to three months after starting pergolide, then every six to 12 months thereafter. Those recommendations also caution that ACTH concentrations may not return to the “PPID unlikely” range even when a horse improves clinically, and that seasonal effects make same-season comparisons especially important. In other words, the value of a recheck isn't simply whether a number normalizes, but whether the veterinarian gets a clearer picture of trajectory. (idppid.com)

Expert commentary in the equine literature has also underscored how nuanced PPID monitoring can be. In a 2021 review for The Horse, equine internal medicine specialist David Rendle noted poor correlation between changes in ACTH and changes in clinical signs in some pergolide-treated horses, and argued that veterinarians should focus heavily on the horse in front of them, not just the lab report. He also recommended early follow-up testing after treatment initiation and highlighted insulin as an important marker when laminitis risk is part of the case. (thehorse.com)

Why it matters: For veterinary professionals, the practical value here may be less about a new diagnostic principle and more about operationalizing best practice. A sponsored recheck pathway can make it easier to bring horses back for objective reassessment during the critical early treatment period, when dose tolerance, compliance, seasonal interpretation, and client understanding all influence outcomes. That could be especially relevant because a clinical audit found that not all pergolide-treated horses receive recommended monitoring in the first one to three months after diagnosis. (sciencedirect.com)

There are still limits to what repeat endocrine testing can answer on its own. Reviews of the evidence note that monitoring should include both endocrine status and clinical response, and that pergolide's effects on insulin and laminitis risk are less consistent than its effects on many clinical signs. That means veterinarians will still need to integrate recheck results with body condition, hoof status, diet, and the horse's broader management plan rather than treating the program as a stand-alone solution. (mdpi.com)

What to watch: The immediate next milestone is the close of the spring 2026 testing window on June 9, followed by the fall window from Aug. 18 to Oct. 13. Longer term, the key question is whether Boehringer publishes aggregate findings from this recheck expansion, particularly around treatment response patterns, dose adjustment decisions, and how repeat testing changes case management in practice. (equimanagement.com)